Oncogenic Forms of ABL Family Kinases

  • Ruibao Ren
Part of the Molecular Biology Intelligence Unit book series (MBIU)


Disruption of the auto-inhibitory structure of ABL and ARG activates their kinase activity and oncogenic potential. The oncogenic forms of ABL family kinases, v-ABL, BCR-ABL, TEL-ABL, NUP214-ABL, EML1-ABL, and TEL-ARG, are implicated in a variety of hematological malignancies. The tyrosine kinase activity of all these oncoproteins is essential for the neoplastic transformation, yet additional activities, particularly those of the fusion partners of the ABL kinases, play important roles in determining the lineage and severity of the neoplastic transformation. A better understanding of the mechanism by which the oncogenic forms of ABL family kinases act in leukemogenesis will help to advance therapies for related human leukemias, as well as to understand the mechanism of leukemogenesis and he-matopoiesis in general.


Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Noonan Syndrome Hematopoietic Cell Line Interferon Consensus Sequence Binding Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nagar B, Hantschel O, Young MA et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003; 112:859–871.PubMedGoogle Scholar
  2. 2.
    Harrison SC. Variation on an Src-like theme. Cell 2003; 112:737–740.PubMedGoogle Scholar
  3. 3.
    Hantschel O, Nagar B, Guettler S et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003; 112:845–857.PubMedGoogle Scholar
  4. 4.
    Woodring PJ, Hunter T, Wang JY. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 2003; 116:2613–2626.PubMedGoogle Scholar
  5. 5.
    Hernandez SE, Krishnaswami M, Miller AL et al. How do Abl family kinases regulate cell shape and movement? Trends Cell Biol 2004; 14:36–44.PubMedGoogle Scholar
  6. 6.
    Schwartzberg PL, Stall AM, Hardin JD et al. Mice homozygous for the ablml mutation show poor viaility and depletion of selected B and T cell populations. Cell 1991; 65:1165–1175.PubMedGoogle Scholar
  7. 7.
    Tybulewicz VLJ, Crawford CE, Jackson PK et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65:1153–1163.PubMedGoogle Scholar
  8. 8.
    Koleske AJ, Gifford AM, Scott ML et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 1998; 21:1259–1272.PubMedGoogle Scholar
  9. 9.
    Rosenberg N, Witte ON. The viral and cellular forms of the abelson (abl) oncogene. Advances in virus research. Vol 35. New York: Academic Press Inc., 1988:39–81.Google Scholar
  10. 10.
    Melo JV. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88:2375–2384.PubMedGoogle Scholar
  11. 11.
    Papadopoulos P, Ridge SA, boucher CA et al. The novel activation of Abl by Fusion to an ets-related gene, TEL. Cancer Research 1995; 55:34–38.PubMedGoogle Scholar
  12. 12.
    Golub TR, Goga A, Barker GF et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996; 16:4107–4116.PubMedGoogle Scholar
  13. 13.
    Brunei V, Sainty D, Carbuccia N et al. A TEL/ABL fusion gene on chromosome 12p13 in a case of Ph-, BCR-atypical CML. Leukemia 1996; 10:2003.Google Scholar
  14. 14.
    Andreasson P, Johansson B, Carlsson M et al. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 1997; 20:299–304.PubMedGoogle Scholar
  15. 15.
    Van Limbergen H, Beverloo HB, van Drunen E et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001; 30:274–282.PubMedGoogle Scholar
  16. 16.
    Keung YK, Beaty M, Steward W et al. Chronic myelocytic leukemia with eosinophilia, t(9; 12)(q34; p13), and ETV6-ABL gene rearrangement: Case report and review of the literature. Cancer Genet Cytogenet 2002; 138:139–142.PubMedGoogle Scholar
  17. 17.
    Cazzaniga G, Tosi S, Aloisi A et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1; 12)(q25; p13): Molecular cloning of both reciprocal transcripts. Blood 1999; 94:4370–4373.PubMedGoogle Scholar
  18. 18.
    Iijima Y, Ito T, Oikawa T et al. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1; 12)(q25; p13) translocation. Blood 2000; 95:2126–2131.PubMedGoogle Scholar
  19. 19.
    Graux C, Cools J, Melotte C et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36:1084–1089.PubMedGoogle Scholar
  20. 20.
    Ballerini P, Busson M, Fasola S et al. NUP214-ABL1 amplification in t(5; 14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Leukemia 2005; 19:468–470.PubMedGoogle Scholar
  21. 21.
    De Keersmaecker K, Graux C, Odero MD et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9; 14)(q34; q32). Blood 2005.Google Scholar
  22. 22.
    Shore SK, Tantravahi RV, Reddy EP. Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene 2002; 21:8568–8576.PubMedGoogle Scholar
  23. 23.
    Pawson T. Protein modules and signalling networks. Nature 1995; 373:573–580.PubMedGoogle Scholar
  24. 24.
    Raffel GD, Parmar K, Rosenberg N. In vivo association of v-Abl with Shc mediated by a nonphosphotyrosine-dependent SH2 interaction. J Biol Chem 1996; 271:4640–4645.PubMedGoogle Scholar
  25. 25.
    Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11–22.PubMedGoogle Scholar
  26. 26.
    Ulku AS, Der CJ. Ras signaling, deregulation of gene expression and oncogenesis. Cancer Treat Res 2003; 115:189–208.PubMedGoogle Scholar
  27. 27.
    Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 2004; 14:639–647.PubMedGoogle Scholar
  28. 28.
    Bos JL. RAS oncogenes in human cancer: A review [published erratum appears in Cancer Res 1990 Feb 15; 50(4):1352]. Cancer Res 1989; 49:4682–4689.PubMedGoogle Scholar
  29. 29.
    Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995; 181:307–313.PubMedGoogle Scholar
  30. 30.
    Stacey DW, Roudebush M, Day R et al. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes. Oncogene 1991; 6:2297–2304.PubMedGoogle Scholar
  31. 31.
    Prywes R, Foulkes JG, Rosenberg N et al. Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation. Cell 1983; 34:569–579.PubMedGoogle Scholar
  32. 32.
    Parmar K, Huebner RC, Rosenberg N. Carboxyl-terminal determinants of Abelson protein important for lymphoma induction. J Virol 1991; 65:6478–6485.PubMedGoogle Scholar
  33. 33.
    Danial NN, Losman JA, Lu T et al. Direct interaction of Jakl and v-Abl is required for v-Abl-induced activation of STATs and proliferation. Mol Cell Biol 1998; 18:6795–6804.PubMedGoogle Scholar
  34. 34.
    Leonard WJ, O’Shea JJ. Jaks and STATs: Biological implications. Annu Rev Immunol 1998; 16:293–322.PubMedGoogle Scholar
  35. 35.
    Onishi M, Nosaka T, Misawa K et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18:3871–3879.PubMedGoogle Scholar
  36. 36.
    Schwaller J, Parganas E, Wang D et al. Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Mol Cell. 2000; 6:693–704.PubMedGoogle Scholar
  37. 37.
    Limnander A, Danial NN, Rothman PB. v-Abl signaling disrupts SOCS-1 function in transformed preB cells. Mol Cell 2004; 15:329–341.PubMedGoogle Scholar
  38. 38.
    Warren D, Griffin DS, Mainville C et al. The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus. J Virol 2003; 77:4617–4625.PubMedGoogle Scholar
  39. 39.
    Parmar K, Rosenberg N. Ras complements the carboxy terminus of v-Abl protein in lymphoid transformation. J Virol 1996; 70:1009–1015.PubMedGoogle Scholar
  40. 40.
    Daley GQ, Van Etten RA, Jackson PK et al. Nonmyrityolated Abl proteins transform a Factor-dependent hematopoietic cell line. Mol Cell Biol 1992; 12:1864–1871.PubMedGoogle Scholar
  41. 41.
    Kharas MG, Deane JA, Wong S et al. Phosphoinositide 3-kinase signaling is essential for ABL oncogene mediated transformation of B lineage cells. Blood 2004.Google Scholar
  42. 42.
    Varticovski L, Daley GQ, Jackson P et al. Activation of phosphtidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 1991; 11:1107–1113.PubMedGoogle Scholar
  43. 43.
    Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15:177–182.PubMedGoogle Scholar
  44. 44.
    Leslie NR, Downes CP. PTEN: The down side of PI 3-kinase signalling. Cell Signal 2002; 14:285–295.PubMedGoogle Scholar
  45. 45.
    Simpson L, Parsons R. PTEN: Life as a tumor suppressor. Exp Cell Res 2001; 264:29–41.PubMedGoogle Scholar
  46. 46.
    Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.PubMedGoogle Scholar
  47. 47.
    Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70:901–910.PubMedGoogle Scholar
  48. 48.
    Hoffman B, Amanullah A, Shafarenko M et al. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 2002; 21:3414–3421.PubMedGoogle Scholar
  49. 49.
    Zou X, Rudchenko S, Wong K et al. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Rafl, and cyclin-dependent kinases. Genes Dev 1997; 11:654–662.PubMedGoogle Scholar
  50. 50.
    Zou X, Cong F, Coutts M et al. p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce preB lymphoma in vivo. Mol Cell Biol 2000; 20:628–633.PubMedGoogle Scholar
  51. 51.
    Radfar A, Unnikrishnan I, Lee HW et al. pl9(Arf) induces p53-dependent apoptosis during abelson virus-mediated preB cell transformation. Proc Natl Acad Sci USA 1998; 95:13194–13199.PubMedGoogle Scholar
  52. 52.
    Unnikrishnan I, Radfar A, Jenab-Wolcott J et al. p53 mediates apoptotic crisis in primary Abelson virus-transformed preB cells. Mol Cell Biol 1999; 19:4825–4831.PubMedGoogle Scholar
  53. 53.
    Unnikrishnan I, Rosenberg N. Absence of p53 complements defects in Abelson murine leukemia virus signaling. J Virol 2003; 77:6208–6215.PubMedGoogle Scholar
  54. 54.
    Matsumura I, Tanaka H, Kanakura Y. E2F1 and c-Myc in cell growth and death. Cell Cycle 2003; 2:333–338.PubMedGoogle Scholar
  55. 55.
    Cong F, Zou X, Hinrichs K et al. Inhibition of v-Abl transformation by p53 and p19ARF. Oncogene 1999; 18:7731–7739.PubMedGoogle Scholar
  56. 56.
    Kurzrock R, Gutterman J, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319:990–998.PubMedGoogle Scholar
  57. 57.
    Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol 1997; 10:203–222.PubMedGoogle Scholar
  58. 58.
    Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172–183.PubMedGoogle Scholar
  59. 59.
    Ren R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: Studies in a murine model. Oncogene 2002; 21:8629–8642.PubMedGoogle Scholar
  60. 60.
    Ramaraj P, Singh H, Niu N et al. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res 2004; 64:5322–5331.PubMedGoogle Scholar
  61. 61.
    Zhao RC, Jiang Y, Verfaillie CM. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 2001; 97:2406–2412.PubMedGoogle Scholar
  62. 62.
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824–830.PubMedGoogle Scholar
  63. 63.
    Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia. Blood 1998; 92:3829–3840.PubMedGoogle Scholar
  64. 64.
    Pear WS, Miller JP, Xu L et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92:3780–3792.PubMedGoogle Scholar
  65. 65.
    Li S, Ilaria RL, Million RP et al. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189:1399–1412.PubMedGoogle Scholar
  66. 66.
    Koschmieder S, Gottgens B, Zhang P et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105:324–334.PubMedGoogle Scholar
  67. 67.
    Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21:8541–8546.PubMedGoogle Scholar
  68. 68.
    Stentoft J, Pallisgaard N, Kjeldsen E et al. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67:302–308.PubMedGoogle Scholar
  69. 69.
    Bhatia R, Holtz M, Niu N et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701–4707.PubMedGoogle Scholar
  70. 70.
    Lowenberg B. Minimal residual disease in chronic myeloid leukemia. N Engl J Med 2003; 349:1399–1401.PubMedGoogle Scholar
  71. 71.
    Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002; 9:303–307.PubMedGoogle Scholar
  72. 72.
    McWhirter JR, Gaalasso DL, Wang JYJ. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993; 13:7587–7595.PubMedGoogle Scholar
  73. 73.
    Zhang X, Subrahmanyam R, Wong R et al. The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol 2001; 21:840–853.PubMedGoogle Scholar
  74. 74.
    He Y, Wertheim JA, Xu L et al. The coiled-coil domain and Tyrl77 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abi. Blood 2002; 99:2957–2968.PubMedGoogle Scholar
  75. 75.
    Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003; 12:27–37.PubMedGoogle Scholar
  76. 76.
    Pendergast AM, Quilliam LA, Cripe LD et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein. Cell 1993; 75:175–185.PubMedGoogle Scholar
  77. 77.
    Puil L, Liu J, Gish G et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13:764–773.PubMedGoogle Scholar
  78. 78.
    Million RP, Van Etten RA. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 2000; 96:664–670.PubMedGoogle Scholar
  79. 79.
    Sattler M, Mohi MG, Pride YB et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1:479–492.PubMedGoogle Scholar
  80. 80.
    Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489–501.PubMedGoogle Scholar
  81. 81.
    Tartaglia M, Mehler EL, Goldberg R et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29:465–468.PubMedGoogle Scholar
  82. 82.
    Tartaglia M, Niemeyer CM, Fragale A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34:148–150.PubMedGoogle Scholar
  83. 83.
    Kosaki K, Suzuki T, Muroya K et al. PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab 2002; 87:3529–3533.PubMedGoogle Scholar
  84. 84.
    Neel BG, Gu H, Pao L. The’ shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 28:284–293.PubMedGoogle Scholar
  85. 85.
    Goga A, McLaughlin J, Afar DE et al. Alternative signals to RAS for hematopoietic transformation by the Bcr-Abl oncogene. Cell 1995; 82:981–988.PubMedGoogle Scholar
  86. 86.
    Braun BS, Tuveson DA, Kong N et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101:597–602.PubMedGoogle Scholar
  87. 87.
    Chan IT, Kutok JL, Williams IR et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004; 113:528–538.PubMedGoogle Scholar
  88. 88.
    Zhang X, Wong R, Hao SX et al. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood 2001; 97:277–287.PubMedGoogle Scholar
  89. 89.
    Roumiantsev S, de Aos IE, Varticovski L et al. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 2001; 97:4–13.PubMedGoogle Scholar
  90. 90.
    Wertheim JA, Perera SA, Hammer DA et al. Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood 2003; 102:2220–2228.PubMedGoogle Scholar
  91. 91.
    Dai Z, Kerzic P, Schroeder WG et al. Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis. J Biol Chem 2001; 276:28954–28960.PubMedGoogle Scholar
  92. 92.
    Nieborowska-Skorska M, Hoser G, Kossev P et al. Complementary functions of the antiapoptotic protein Al and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 2002; 99:4531–4539.PubMedGoogle Scholar
  93. 93.
    Klejman A, Schreiner SJ, Nieborowska-Skorska M et al. The Src family kinase Hck couples BCR/ ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21:5766–5774.PubMedGoogle Scholar
  94. 94.
    Sexl V, Piekorz R, Moriggl R et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl-and bcr/abl-induced transformation are independent of stat5. Blood 2000; 96:2277–2283.PubMedGoogle Scholar
  95. 95.
    Hu Y, Liu Y, Pelletier S et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36:453–461.PubMedGoogle Scholar
  96. 96.
    Holtschke T, Lohler J, Kanno Y et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996; 87:307–317.PubMedGoogle Scholar
  97. 97.
    Passegue E, Jochum W, Schorpp-Kistner M et al. Chronic myeloid leukemia with increased granu-locyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001; 104:21–32.PubMedGoogle Scholar
  98. 98.
    Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004; 119:431–443.PubMedGoogle Scholar
  99. 99.
    Ishida D, Kometani K, Yang H et al. Myeloproliferative stem cell disorders by deregulated Rapl activation in SPA-1-deficient mice. Cancer Cell 2003; 4:55–65.PubMedGoogle Scholar
  100. 100.
    Tamura T, Nagamura-Inoue T, Shmeltzer Z et al. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 2000; 13:155–165.PubMedGoogle Scholar
  101. 101.
    Stork PJ. Does Rap 1 deserve a bad Rap? Trends Biochem Sci 2003; 28:267–275.PubMedGoogle Scholar
  102. 102.
    Hao SX, Ren R. Expression of ICSBP is downregulated in Bcr-Abl-induced murine CML-like disease, and forced coexpression of ICSBP inhibits the Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000; 20:1149–1161.PubMedGoogle Scholar
  103. 103.
    Schmidt M, Nagel S, Proba J et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998; 91:22–29.PubMedGoogle Scholar
  104. 104.
    Bruchova H, Borovanova T, Klamova H et al. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma 2002; 43:1289–1295.PubMedGoogle Scholar
  105. 105.
    Yang MY, Liu TC, Chang JG et al. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 2003; 101:3205–3211.PubMedGoogle Scholar
  106. 106.
    Mizuchi D, Kurosu T, Kida A et al. BCR/ABL activates Rapl and B-Raf to stimulate the MEK/ Erk signaling pathway in hematopoietic cells. Biochem Biophys Res Commun 2005; 326:645–651.PubMedGoogle Scholar
  107. 107.
    McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 1989; 9:1866–1874.PubMedGoogle Scholar
  108. 108.
    Castellanos A, Pintado B, Weruaga E et al. A BCR-ABL(pl90) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood 1997; 90:2168–2174.PubMedGoogle Scholar
  109. 109.
    Heisterkamp N, Jenster G, ten Hoeve J et al. Acute leukemia in bcr/abl transgenic mice. Nature 1990; 344:251–253.PubMedGoogle Scholar
  110. 110.
    Voncken JW, Griffiths S, Greaves MF et al. Restricted oncogenicity of BCR/ABL pl90 in transgenic mice. Cancer Res 1992; 52:4534–4539.PubMedGoogle Scholar
  111. 111.
    Voncken JW, Kaartinen V, Pattengale PK et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 1995; 86:4603–4611.PubMedGoogle Scholar
  112. 112.
    Huettner CS, Zhang P, Van Etten RA et al. Reveribility of acute B-cell leukemia induced by BCR-ABL1. Nature Genetics 2000; 24:57–60.PubMedGoogle Scholar
  113. 113.
    Gross AW, Ren R. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells in vivo. Oncogene 2000; 19:6286–6296.PubMedGoogle Scholar
  114. 114.
    Million RP, Harakawa N, Roumiantsev S et al. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 2004; 24:4685–4695.PubMedGoogle Scholar
  115. 115.
    Jousset C, Carron C, Boureux A et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 1997; 16:69–82.PubMedGoogle Scholar
  116. 116.
    Hannemann JR, McManus DM, Kabarowski JH et al. Haemopoietic transformation by the TEL/ ABL oncogene. Br J Haematol 1998; 102:475–485.PubMedGoogle Scholar
  117. 117.
    Kim CA, Phillips ML, Kim W et al. Polymerization of the SAM domain of TEL in leukemogen-esis and transcriptional repression. EMBO J 2001; 20:4173–4182.PubMedGoogle Scholar
  118. 118.
    Million RP, Aster J, Gilliland DG et al. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9; 12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 2002; 99:4568–4577.PubMedGoogle Scholar
  119. 119.
    Okuda K, Golub TR, Gilliland DG et al. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 1996; 13:1147–1152.PubMedGoogle Scholar
  120. 120.
    Wertheim JA, Miller JP, Xu L et al. The biology of chronic myelogenous leukemia: Mouse models and cell adhesion. Oncogene 2002; 21:8612–8628.PubMedGoogle Scholar
  121. 121.
    Ren R. Modeling the dosage effect of oncogenes in leukemogenesis. Curr Opin Hematol 2004; 11:25–34.PubMedGoogle Scholar
  122. 122.
    Okuda K, Oda A, Sato Y et al. Signal transduction and cellular functions of the TEL/ARG oncoprotein. Leukemia 2005.Google Scholar
  123. 123.
    Okuda K, Sato Y, Sonoda Y et al. The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors. Int J Hematol 2004; 79:138–146.PubMedGoogle Scholar
  124. 124.
    Soekarman D, von Lindern M, Daenen S et al. The translocation (6; 9) (p23; q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 1992; 79:2990–2997.PubMedGoogle Scholar
  125. 125.
    von Lindern M, Fornerod M, van Baal S et al. The translocation (6; 9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992; 12:1687–1697.Google Scholar
  126. 126.
    Ryan KJ, Wente SR. The nuclear pore complex: A protein machine bridging the nucleus and cytoplasm. Curr Opin Cell Biol 2000; 12:361–371.PubMedGoogle Scholar
  127. 127.
    Eudy JD, Ma-Edmonds M, Yao SF et al. Isolation of a novel human homologue of the gene coding for echinoderm microtubule-associated protein (EMAP) from the Usher syndrome type la locus at 14q32. Genomics 1997; 43:104–106.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2006

Authors and Affiliations

  • Ruibao Ren
    • 1
  1. 1.Rosenstiel Basic Medical Sciences Research Center, MS029, Department of BiologyBrandeis UniversityWalthamUSA

Personalised recommendations